NDLI: Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity.

Please wait, while we are loading the content...

Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.

Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction.

Linezolid desensitization for a patient with multiple medication hypersensitivity reactions.

Concomitant administration of pneumococcal-23 and zoster vaccines provides adequate herpes zoster coverage.

Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?

Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study.

Apparent argatroban resistance in a patient with elevated factor VIII levels.

Medication errors in HIV-infected hospitalized patients: a pharmacist's impact.

Plan B and the German Catholic bishops.

Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.

Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis.

Impact of severe hypothyroidism on cyclophosphamide disposition and routes of metabolism and transport in a patient with treatment-resistant lupus nephritis.

Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature.

Cholestatic jaundice as a result of combination designer supplement ingestion.

Drug interactions and the pharmacist: focus on everolimus.

Mirabegron: ß3-adrenergic receptor agonist for the treatment of overactive bladder.

Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation.

A tool to characterize the components of pharmacist interventions in clinical pharmacy services: the DEPICT project.

Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment.

The role of denosumab for prevention of skeletal-related complications in multiple myeloma.

Herpes simplex virus encephalitis pharmacotherapy: alternative treatment options.

The Patient Protection and Affordable Care Act: implications for pediatric pharmacy practice.

New obesity agents: lorcaserin and phentermine/topiramate.

Time to finger point or fix? An invitation to join ongoing efforts to promote ethical authorship and other good publication practices.

Medical applications for pharmacists using mobile devices.

Risk of injury associated with skeletal muscle relaxant use in older adults.

Standard versus prolonged doripenem infusion for treatment of gram-negative infections.

Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity.

Year: 2012 Volume: 46

Year: 2011 Volume: 45

Year: 2010 Volume: 44

Year: 2009 Volume: 43

Year: 2008 Volume: 42

Year: 2007 Volume: 41

Year: 2003 Volume: 37

Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Huskey, Amanda M. Thomas, Cassandra C. Waddell, James Aubrey
Description	Country affiliation: United States Author Affiliation: Huskey AM ( College of Pharmacy, University of Tennessee, Knoxville, TN, USA.)
Abstract	OBJECTIVE: To report the development of morbilliform rash and serotonin toxicity after the addition of milnacipran to a patient's medication therapy. CASE SUMMARY: A 57-year-old white female presented to the emergency department because of a full-body morbilliform rash, which appeared 9 days after initiation of milnacipran 50 mg twice daily. In the emergency department the patient's vital signs were: heart rate 121 beats/min, blood pressure 180/100 mm Hg, and temperature 38.9 °C. The patient reported diarrhea, nausea, dizziness, restlessness, and increased muscle pain. Her history included recurrent breast cancer first diagnosed in 1999, hypertension, fibromyalgia, depression, osteopenia, gastroesophageal reflux disease, insomnia, and endometriosis. Her home medications included milnacipran, fluoxetine, alprazolam, zolpidem, zoledronic acid, anastrozole, doxepin, ranitidine, levocetirizine, doxazosin, tramadol, vitamin D, and ferrous gluconate. The patient's increased heart rate, blood pressure, and temperature, as well as restlessness, self-reported diarrhea and nausea, and self-reported increase in muscle pain, indicated serotonin toxicity. Milnacipran, fluoxetine, and tramadol were discontinued, while doxepin was continued. Treatment consisted of acetaminophen, diphenhydramine, methylprednisolone, promethazine, and hydralazine 10 mg intravenously. The following morning all vital signs were within normal limits and the patient's diarrhea, nausea, dizziness, restlessness, and muscle pain resolved. She was discharged the following morning. The rash had resolved after day 2 of hospital discharge, which was the fourth day after discontinuation of milnacipran. DISCUSSION: Given the patient's symptoms, the timing of symptom onset, the patient's history, and findings on physical examination, as well as use of the Naranjo probability scale, milnacipran was deemed the probable cause of the morbilliform reaction and serotonin toxicity. Only 1 case report of rash and 2 case reports of serotonin syndrome associated with milnacipran have been reported. CONCLUSIONS: It is important to increase awareness of the possibility of developing morbilliform rash and serotonin toxicity with milnacipran therapy, as both conditions can be associated with poor outcomes if not detected early and treated appropriately.
File Format	HTM / HTML
ISSN	10600280
Issue Number	7-8
Volume Number	47
e-ISSN	15426270
Journal	Annals of Pharmacotherapy
Language	English
Publisher	SAGE Publications
Publisher Date	2013-07-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmaceutical Science Cyclopropanes Adverse Effects Exanthema Chemically Induced Diagnosis Serotonin Syndrome Antidepressive Agents Complications Female Humans Middle Aged Case Reports Journal Article
Content Type	Text
Resource Type	Case study Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Catastrophic reversible cerebral vasoconstriction syndrome associated with serotonin syndrome.

First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis.

Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.

A case of severe parkinsonism associated with short-term treatment with milnacipran.

A postoperative blue rash: indigo carmine dye extravasation.

Rash associated with dabigatran etexilate.

Photosensitivity associated with selective serotonin reuptake inhibitors.

Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome.

Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran.

Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity.

Similar Documents

Catastrophic reversible cerebral vasoconstriction syndrome associated with serotonin syndrome.

First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis.

Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.

A case of severe parkinsonism associated with short-term treatment with milnacipran.

A postoperative blue rash: indigo carmine dye extravasation.

Rash associated with dabigatran etexilate.

Photosensitivity associated with selective serotonin reuptake inhibitors.

Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome.

Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran.

Occurrence of milnacipran-associated morbilliform rash and serotonin toxicity.